VERU
VERU INC.
$3.00
-7.98%
$48.2M
No data for this timeframe.
Vol
Market Cap$48.2M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders26 funds
Inst. Value$4.7M
Inst. Activity1 buys / 3 sells
Reddit Sentiment67° Warm
SEC Reports5
Recent Activity
Jun 4, 2026
SEC
Veru Inc. entered a clinical supply agreement with Novo Nordisk under which Novo Nordisk will supply Wegovy (semaglutide
8-K — Impact 6/10
May 13, 2026
SEC
Veru reported fiscal Q2 2026 net loss of $2.7M (-$0.12/share) vs $7.9M (-$0.54/share) a year ago, beating the $-0.37 con
8-K — Impact 4/10
May 13, 2026
SEC
Veru reported Q2 2026 net loss of $2.7M ($0.12/share), narrower than the $7.9M loss a year ago, driven by lower R&D and
PRESS-RELEASE — Impact 5/10
May 4, 2026
Insider
STEINER MITCHELL SHUSTER was granted 604,000 shares
President and CEO
May 4, 2026
Insider
Greco Michele was granted 164,000 shares
Chief Admin Officer and CFO
May 4, 2026
Insider
Katzovitz Loren Mark was granted 102,000 shares
Director
Inst.
BLAIR WILLIAM & CO/IL — ADD
48,000 shares ($102.7K)
Inst.
MORGAN STANLEY — NEAR_EXIT
4,270 shares ($9.1K)
Price Targets
$24.50
+716.7% upside
Strong Buy
Current $3.00
Low $24.00
Median $24.50
High $25.00
2 analysts
$24.00
$25.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 15, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Dec 18, 2025 | Canaccord Genuity | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.32 ▼ -3.2% | $-0.34 — $-0.30 | 40% YoY | 2 |
| Next Q | $-0.33 ▲ +1.5% | $-0.34 — $-0.31 | -461% YoY | 2 |
| Current FY | $-1.20 ▼ -0.8% | $-1.43 — $-0.96 | -12% YoY | 2 |
| Next FY | $-0.98 ▲ +17.9% | $-1.13 — $-0.84 | 18% YoY | 2 |
Latest Reports
BULLISH
8-K
6/10
Veru Inc. entered a clinical supply agreement with Novo Nordisk under which Novo Nordisk will supply Wegovy (semaglutide
Jun 4, 2026
NEUTRAL
8-K
4/10
Veru reported fiscal Q2 2026 net loss of $2.7M (-$0.12/share) vs $7.9M (-$0.54/share) a year ago, beating the $-0.37 con
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Alyeska Investment Group, L.P. | $2.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.2M | — |
| BlackRock, Inc. | $252.3K | — |
| VANGUARD FIDUCIARY TRUST CO | $178.2K | — |
| RENAISSANCE TECHNOLOGIES LLC | $153.0K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | STEINER MITCHELL | A | $0.00 |
| May 4, 2026 | Greco Michele | A | $0.00 |
| May 4, 2026 | Katzovitz Loren | A | $0.00 |
| May 4, 2026 | Hyun Grace | A | $0.00 |
| May 4, 2026 | Rankowitz Michael | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
26 institutional holders with $4.7M total value (2,157,252 shares) as of 2026-Q1. Top holders: Alyeska, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 1,000,000 | $2.2M | 46.8% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 539,382 | $1.2M | 25.2% | — |
| 3 | BlackRock, Inc. | 114,169 | $252.3K | 5.3% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 80,653 | $178.2K | 3.8% | — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 69,250 | $153.0K | 3.2% | — |
| 6 | RAYMOND JAMES FINANCIAL INC | 67,561 | $149.3K | 3.2% | ADD +48.3% |
| 7 | STATE STREET CORP | 55,004 | $121.6K | 2.6% | NEAR_EXIT -75.4% |
| 8 | BLAIR WILLIAM & CO/IL | 48,000 | $106.1K | 2.2% | ADD +26.3% |
| 9 | CITADEL ADVISORS LLC | 44,482 | $98.3K | 2.1% | — |
| 10 | CITADEL ADVISORS LLC | 25,600 | $56.6K | 1.2% | — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12,771 | $28.2K | 0.6% | — |
| 12 | ROYAL BANK OF CANADA | 12,239 | $27.0K | 0.6% | TRIM -34.2% |
| 13 | CITADEL ADVISORS LLC | 11,800 | $26.1K | 0.6% | — |
| 14 | Mariner, LLC | 11,381 | $25.2K | 0.5% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10,200 | $22.5K | 0.5% | — |
| 16 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 10,000 | $22.1K | 0.5% | — |
| 17 | Allworth Financial LP | 7,817 | $17.3K | 0.4% | — |
| 18 | WELLS FARGO & COMPANY/MN | 7,005 | $15.5K | 0.3% | TRIM -60.5% |
| 19 | Vanguard Global Advisers, LLC | 5,821 | $12.9K | 0.3% | — |
| 20 | MORGAN STANLEY | 4,247 | $9.4K | 0.2% | NEAR_EXIT -76.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BLAIR WILLIAM & CO/IL | ADD | 38,000 | 48,000 | +26.3% | $102.7K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 17,994 | 4,270 | -76.3% | $9.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 18,010 | 699 | -96.1% | $1.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 899 | 355 | -60.5% | $760.00 | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 2,481 | 2 | -99.9% | — | 2025-Q3 |
| STATE STREET CORP | NEAR_EXIT | 2,234,038 | 550,069 | -75.4% | $320.0K | 2025-Q2 |
| RAYMOND JAMES FINANCIAL INC | ADD | 139,227 | 206,405 | +48.3% | $120.1K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 375,291 | 65,000 | -82.7% | $37.8K | 2025-Q2 |
| Vanguard Personalized Indexing Management, LLC | ADD | 11,892 | 14,997 | +26.1% | $8.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 73,704 | 10,807 | -85.3% | $6.3K | 2025-Q2 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 6,730 | 9,285 | +38.0% | $5.4K | 2025-Q2 |
| ROYAL BANK OF CANADA | TRIM | 8,140 | 5,360 | -34.2% | $3.0K | 2025-Q2 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 300 | 889 | +196.3% | $517.00 | 2025-Q2 |
| CWM, LLC | TRIM | 3,550 | 2,481 | -30.1% | $1.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 448,565 | 1,966,781 | +338.5% | $963.7K | 2025-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 2,300,000 | 1,000,000 | -56.5% | $490.1K | 2025-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 406,755 | 666,294 | +63.8% | $326.6K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,464,099 | 376,367 | -74.3% | $184.5K | 2025-Q1 |
| Atria Investments, Inc | ADD | 171,707 | 253,256 | +47.5% | $124.1K | 2025-Q1 |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | 34,195 | 139,227 | +307.2% | $68.2K | 2025-Q1 |
| Lido Advisors, LLC | ADD | 12,167 | 24,021 | +97.4% | $11.8K | 2025-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 5,000 | 6,730 | +34.6% | $3.3K | 2025-Q1 |
| FMR LLC | TRIM | 8,222 | 5,112 | -37.8% | $2.5K | 2025-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | 106,109 | 253,180 | +138.6% | $125.00 | 2025-Q1 |
| CWM, LLC | DOUBLED | 764 | 3,550 | +364.7% | $2.00 | 2025-Q1 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | STEINER MITCHELL SHUSTER | President and CEO | AWARD | 604,000 | — | — |
| May 4, 2026 | Greco Michele | Chief Admin Officer and CFO | AWARD | 164,000 | — | — |
| May 4, 2026 | Katzovitz Loren Mark | Director | AWARD | 102,000 | — | — |
| May 4, 2026 | Hyun Grace | Director | AWARD | 97,000 | — | — |
| May 4, 2026 | Rankowitz Michael L | Director | AWARD | 100,000 | — | — |
| May 4, 2026 | Lu Lucy | Director | AWARD | 104,000 | — | — |
| May 4, 2026 | BARNETTE K GARY | Chief Scientific Officer | AWARD | 160,000 | — | — |
| May 4, 2026 | FISCH HARRY | Chief Corporate Officer | AWARD | 160,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.
BULLISH
8-K
6/10
Veru Inc. entered a clinical supply agreement with Novo Nordisk under which Novo Nordisk will supply
Jun 4, 2026
NEUTRAL
8-K
4/10
Veru reported fiscal Q2 2026 net loss of $2.7M (-$0.12/share) vs $7.9M (-$0.54/share) a year ago, be
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Veru reported Q2 2026 net loss of $2.7M ($0.12/share), narrower than the $7.9M loss a year ago, driv
May 13, 2026
BEARISH
S-3
7/10
VERU INC filed a shelf registration (S-3) for up to $200 million in securities, including common sto
Apr 7, 2026
BEARISH
S-3
7/10
VERU filed an S-3 shelf registration to register 23.8 million shares of common stock issuable upon e
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$24.50 mean target
+716.7% upside
Strong Buy (1.00)
$24.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $3.00 |
| Target Low | $24.00 |
| Target Mean | $24.50 |
| Target Median | $24.50 |
| Target High | $25.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.32 | $-0.34 | $-0.30 | 39.9% | -3.2% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.33 | $-0.34 | $-0.31 | -461.1% | +1.5% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-09-30 |
$-1.20 | $-1.43 | $-0.96 | -11.7% | -0.8% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-09-30 |
$-0.98 | $-1.13 | $-0.84 | 17.6% | +17.9% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.320 | |
| 7d ago | $-0.320 | |
| 30d ago | $-0.310 | -0.010 |
| 60d ago | $-0.310 | -0.010 |
| 90d ago | $-0.310 | -0.010 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 15, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Dec 18, 2025 | Canaccord Genuity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 4, 2026
short_volume
Short Volume: VERU — 56.1% short (30.1M / 53.6M)
Short: 30,059,959 | Exempt: 244,826 | TRF Vol: 53,573,337 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
<p align="center"><strong><em>--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i</em></stro
May 6, 2026
earnings_calendar
VERU Q2 2026 Earnings Scheduled — 2026-05-06
Mar 9, 2026
earnings
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
<p align="center"><strong><em>-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn m